[Form 4] Oncology Institute, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) director Mark L. Pacala reported multiple open-market sales of company common stock. On 11/18/2025, he sold 2,160, 1,210, and 46,630 shares of TOI common stock, each at a price of $4 per share, according to the Form 4.

After these transactions, Pacala directly beneficially owned 174,971 shares of TOI common stock. The filing notes that the sales represent shares acquired from previously vested restricted stock unit (RSU) awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacala Mark L

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		S(1)		2,160	D	$4	222,811	D
Common Stock	11/18/2025		S(1)		1,210	D	$4	221,601	D
Common Stock	11/18/2025		S(1)		46,630	D	$4	174,971	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents sale of Common Stock acquired from previously vested RSU awards.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mark L. Pacala	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oncology Institute (TOI) report in this Form 4?

The Form 4 reports that director Mark L. Pacala sold shares of Oncology Institute, Inc. (TOI) common stock in multiple transactions on 11/18/2025.

How many TOI shares did Mark L. Pacala sell and at what price?

On 11/18/2025, Mark L. Pacala sold 2,160, 1,210, and 46,630 shares of TOI common stock, each at a price of $4 per share.

How many Oncology Institute (TOI) shares does the director own after these sales?

Following the reported transactions, Mark L. Pacala beneficially owned 174,971 shares of Oncology Institute, Inc. common stock in direct ownership.

What is Mark L. Pacala’s relationship to Oncology Institute (TOI)?

Mark L. Pacala is reported as a director of Oncology Institute, Inc. (TOI) on this Form 4 and filed the form as a single reporting person.

What is the source of the TOI shares that were sold in this Form 4?

The explanation states that the sale of TOI common stock represents shares acquired from previously vested RSU awards.

Does this TOI Form 4 involve any derivative securities like options or warrants?

The filing includes a section for derivative securities, but no derivative transactions are listed; only common stock sales appear in the reported transactions.